Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
For Journalists
Manager
Telephone: 412-647-9966
Senior Director
Telephone: 412-586-9764
Patient & Other Inquiries



Magee Clinical Trial Opens to Examine Therapies on Invasive Lobular Breast Cancer

PITTSBURGH, Oct. 6, 2015 – Physicians at Magee-Womens Hospital of UPMC and the University of Pittsburgh Cancer Institute (UPCI) have opened a clinical trial to learn more about how three commonly prescribed anti-estrogen therapies affect the tumor tissue of patients diagnosed with invasive lobular breast cancer (ILC), a less common and understudied type of breast cancer. This is the first study of its kind to employ a prospective clinical trial approach to understanding ILC, doctors said.
 
Patients with ILC represent 5 to 15 percent of breast cancer patients, and it is unclear how their cancers differ from those with invasive ductal carcinoma (IDC), which is much more common. Previous laboratory models studied by researchers at the Womens Cancer Research Center (WCRC) at UPCI and Magee-Womens Research Institute and Foundation (MWRIF) suggest that patients with ILC may respond differently to anti-estrogen therapies commonly given to those with either cancer type.
 
“Currently, there is a one-size-fits-all approach in how we treat patients with invasive lobular breast cancer and invasive ductal carcinoma,” said Rachel Jankowitz, M.D., assistant professor of medicine in the University of Pittsburgh Division of Hematology/Oncology, medical director of the Magee-Womens Hospital Breast and Ovarian Cancer Risk Assessment and Prevention Program, and the trial’s principal investigator. “Our goal is to increase understanding of how to tailor treatment for women with ILC in order to ultimately improve their long-term outcomes.”
 
Study participants will be randomized into three groups that will receive one of three different drugs that are commonly used in breast cancer treatment during the 21-day period before surgery is performed.
 
“Our trial will examine how ILC tumor tissue responds to the current standards of care – treatment with either Tamoxifen or Anastrazole, as compared to Fulvestrant, a drug currently approved only to treat advanced breast cancer,” said Steffi Oesterreich, Ph.D. , professor in the Pitt Department of Pharmacology and Chemical Biology, and the WCRC’s director of education, who will direct the analyses of the breast tumor tissues to identify molecular markers of response or resistance to therapies.
 
Dr. Jankowitz’s team plans to open the study at several other large cancer centers that have expressed interest in enrolling their patients through the Translational Breast Cancer Research Consortium (TBCRC), a collaborative group of 17 clinical sites that aims to conduct innovative and high-impact clinical trials for breast cancer.
 
The trial is supported by the Susan G. Komen Foundation and by AstraZeneca.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit www.healthwise.org

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

UPMC
Pittsburgh, PA, USA | UPMC.com